Key Points for Decision Makers {#d30e364}
==============================

• A large proportion of patients with atrial fibrillation (AF) and moderate to high risk of stroke do not receive thromboprophylaxis or are not optimally controlled with vitamin K antagonists (VKAs).

• Rivaroxaban (Xarelto^®^), a once-daily agent, is one of the novel oral anticoagulants that are now recommended by recent international guidelines as broadly preferable to VKAs for patients with non-valvular AF.

• The present analysis suggests that rivaroxaban is a cost-effective alternative to warfarin therapy for the prevention of stroke in patients with AF in the Belgian healthcare setting.

Introduction {#Sec1}
============

Atrial fibrillation (AF) is associated with an increase in the risk of ischemic stroke by a factor of four to five and accounts for 15--25 % of all stroke cases \[[@CR1], [@CR2]\]. Stroke is a major cause of long-term disability and death. According to the WHO, in 2004, stroke and other cerebrovascular diseases accounted for 5.7 million deaths worldwide (9.7 % of total) and was the second leading cause of death after coronary heart disease \[[@CR3], [@CR4]\]. In Belgium, the gender- and age-adjusted incidence rate for first-ever and recurrent stroke is estimated to be 185 per 100,000 inhabitants per year \[[@CR5]\]. Given that about one-fifth of all stroke cases are attributable to AF \[[@CR6]\], it is thought that AF causes 4,000 stroke cases per year in Belgium.

An individual's risk of AF-related stroke can be estimated with CHADS~2~ scores (scale ranging from 0 to 6, with a greater risk of stroke indicated by higher scores) and reduced by two-thirds with effective anticoagulation. Vitamin K antagonists (VKAs), such as warfarin, have been the mainstay of anticoagulant therapy for over half a century \[[@CR7]\]. In Belgium, most AF patients with moderate to high risk of stroke (CHADS~2~ score ≥2) are currently treated with VKA therapy (±50 % of patients) or aspirin (±25 %), or receive other non-pharmacological treatments \[[@CR8], [@CR9]\]. There are, however, some disadvantages associated with VKA therapy. These agents have a slow onset of action and possess a narrow therapeutic window. Due to pharmacogenetic variability and the various interactions VKAs have with both food and other drugs, it tends to be difficult to maintain a patient within the optimal international normalized ratio (INR) range of 2.0--3.0. As a result, there is a need for frequent and lifelong blood monitoring \[[@CR10]\].

Recently, novel oral anticoagulants (NOACs), rivaroxaban (once daily), dabigatran etexilate (twice daily), apixaban (twice daily) have been approved as possible alternatives to VKA therapy. Rivaroxaban (Xarelto^®^) is a highly selective, oral, once daily, direct factor Xa inhibitor that has shown a favourable risk-benefit profile compared with warfarin in the prevention of stroke and systemic embolism events. In the phase III study (ROCKET AF), rivaroxaban demonstrated a 21 % risk reduction in event rate for stroke and systemic embolism (hazard ratio \[HR\] 0.79; 95 % CI 0.66--0.96; *p* \< 0.001 for non-inferiority) while on-treatment compared with warfarin, and a significant reduction in the most serious complications of warfarin therapy, i.e. intracranial haemorrhage and fatal bleeding \[[@CR11]\]. Since then the product has been approved for stroke prevention in non-valvular AF by both the US FDA and the European Medicines Agency (EMA), and in many countries worldwide. Dabigatran etexilate and apixaban also showed a favourable risk-benefit profile compared with warfarin in their phase III trials (RE-LY and ARISTOTLE, respectively) \[[@CR12], [@CR13]\]. On the basis of the clinical evidence that has arisen in the last few years, the most recent version of the European Society of Cardiology guidelines for the management of AF now recommends the NOACs as broadly preferable to VKAs in the vast majority of patients with non-valvular AF, when used as studied in the clinical trials \[[@CR14]\].

Warfarin therapy is both effective and inexpensive, but treatment with rivaroxaban offers some distinct advantages over warfarin. Therefore, the aim of the present study was to evaluate the cost-effectiveness of rivaroxaban versus warfarin for the prevention of stroke in patients with AF at moderate (CHADS~2~ score = 2) to high risk (CHADS~2~ score \>2) in the Belgian healthcare setting. To our knowledge, this is one of the very first studies evaluating this hypothesis.

Methods {#Sec2}
=======

Model Structure {#Sec3}
---------------

For this study, a Markov cost-effectiveness model was designed that can be used by decision makers to systematically assess the comparative costs and outcomes of a new treatment compared with warfarin (Fig. [1](#Fig1){ref-type="fig"}). Patients with a mean age of 73 years and suffering from non-valvular AF at moderate (CHADS~2~ score = 2) to high risk of stroke (CHADS~2~ score = 3 or higher) enter the model and receive chronic treatment with either rivaroxaban (new treatment, 15--20 mg oral tablet, once daily) or dose-adjusted warfarin (comparator treatment, target INR of 2.5). In both cases, patients received aspirin after discontinuation of the initial treatment. The evaluation was carried out from the perspective of the Belgian health care payer (i.e. National Institute for Health and Disability Insurance and patients).Fig. 1Structure of the model. *Afib* atrial fibrillation, *IC* intracranial, *MI* myocardial infarction, *Tx* treatment

The model was populated with clinical data from the pivotal head-to-head phase III ROCKET AF trial and local cost estimates in order to calculate an incremental cost-effectiveness ratio (ICER) of rivaroxaban compared with warfarin. Direct comparisons with dabigatran or apixaban were not done as head-to-head trials do not exist and both molecules were not yet approved at the time of the ROCKET trial. The cycle length of the model was 3 months and patients progressed between states according to the event rates as observed in the trial. Patients experiencing an ischemic stroke were presumed to continue with their anticoagulation therapy if they were already on therapy and/or to (re)-initiate the therapy if they had discontinued. Modified Rankin Scores (mRS), a commonly used scale for measuring the degree of disability or dependence in the daily activities, were recorded in the ROCKET AF trial and used to categorize strokes as either minor (mRS score 0--2) or major (mRS score 3--5). In the post-stroke, post-myocardial infarction and post-intracranial bleed states, patients continued to be at risk of experiencing secondary events according to the risk profile of the drug they had been re-initiated on. These secondary events are minor bleeds, major extracranial bleed, myocardial infarction and systemic embolisms. The patients will not be sent to the respective secondary health states but instead will be given a pay-off corresponding to the cost and (dis)utility of those acute events. If the utility of the secondary event is higher than the utility of the primary health state, the utility from the primary health state will be applied. This is to prevent the eventual return of these patients to a less severe health state (e.g. from post-stroke to stable AF) where the utility and cost consequences of the more severe health states would not be applied. The main complications, classified as either transient (non-boxed states in Fig. [1](#Fig1){ref-type="fig"}) or permanent (boxed) health states, were death, ischemic stroke, systemic embolism, bleeding and myocardial infarction. Bleeding events were categorized as major extracranial, clinically relevant non-major (CRNM) extracranial, and intracranial as defined in the manuscript describing the rationale and design of the ROCKET AF study \[[@CR15]\].

Clinical Effectiveness and Treatment Discontinuation {#Sec4}
----------------------------------------------------

The main clinical data inputs were based on the safety on treatment results of the ROCKET AF trial and are presented in Table [1](#Tab1){ref-type="table"}. ROCKET AF was found to be the only single trial that provides head-to-head clinical evidence on efficacy and safety of rivaroxaban in stroke prevention in AF compared with adjusted-dose warfarin. Rivaroxaban was associated with significant reductions in intracranial haemorrhage (0.5 vs. 0.7 %; *p* = 0.02) and fatal bleeding (0.2 vs. 0.5 %; *p* = 0.003). As there is discussion on the most appropriate statistical method to evaluate results of non-inferiority trials \[[@CR16], [@CR17]\], results based on the intention-to-treat population are also presented. Baseline event rates were obtained from the warfarin arm of the trial and converted into quarterly rates for use in the modelling analysis as described by Briggs et al. \[[@CR18]\]. Relative risks of events from ROCKET AF for rivaroxaban were applied to these event rates observed with warfarin. For example, the baseline risk of ischaemic stroke was 1.42 % per year in the warfarin arm of the study, which was converted into a quarterly rate of 0.36 % \[[@CR11]\]. For rivaroxaban, this rate was multiplied by a relative risk of 0.94, resulting in a quarterly event rate of 0.34 %. Event rates for systemic embolism, bleeding events, and myocardial infarction were derived in an identical manner. Background mortality, based on Belgian life tables \[[@CR19]\], and mortality specific to the clinical events were included in the model (Table [2](#Tab2){ref-type="table"}). Estimates for event-related mortality were based on results of the ROCKET AF study, except for the long-term mortality rates following major stroke \[[@CR2]\] and myocardial infarction \[[@CR20]\] which were obtained from the literature. Patients could transition to the death health state from all other health states. It was assumed there were no event-related case fatalities in the minor stroke, post-minor stroke, CRNM extracranial bleed, post-CRNM and post-major extracranial bleed, and systemic embolism health states. Treatment discontinuation rates for rivaroxaban (8.90 % in the initial and 4.39 % in subsequent cycles) and warfarin (8.00 % in the initial and 4.46 % in subsequent cycles) were also derived from the ROCKET AF trial.Table 1Overview clinical input data (95 % CI)Event (source)Baseline risk \[%\] (3 months)RR rivaroxaban vs. warfarinIschemic stroke \[[@CR11]\]0.36 (0.27--0.45 %)0.94 (0.75-- 1.17) Of which major \[[@CR31]\]59.00 (41.84--62.66 %)*--* Of which minor41.00 (37.34--58.16 %)--Systemic embolism \[[@CR11]\]0.05 (0.00--0.76 %)0.23 (0.09--0.61)Extracranial CRNM bleed \[[@CR11]\]2.97 (1.79--5.04 %)1.04 (0.96--1.13)Extracranial major bleed \[[@CR11]\]0.69 (0.24--1.90 %)1.14 (0.98--1.33)Intracranial bleed \[[@CR11]\]0.19 (0.03--1.04 %)0.67 (0.47--0.93)Myocardial infarction \[[@CR11]\]0.28 (0.05--1.22 %)0.81 (0.63--1.06)*CRNM* clinically relevant non-major, *RR* relative riskTable 2Mortality rates (95 % CI)Health state (source)Event-related mortality rate per 3-month cycle \[%\]Major stroke \[[@CR32]\]12.6 (9.4--15.7 %)Post-major stroke \[[@CR2], [@CR32]\]2.63 (0.91--13.50 %)Minor strokeN/A^a^Systemic embolismN/A^a^Major extracranial bleed \[[@CR32]\]1.55 (1.16--1.94 %)Intracranial bleed \[[@CR32]\]38.85 (29.14--48.56 %)Post-intracranial bleed \[[@CR32]\]2.63 (0.91--13.5 %)^b^Myocardial infarction \[[@CR32]\]9.69 (7.27--12.11 %)Post-myocardial infarction \[[@CR20], [@CR32]\]2.68 (0--6.75 %)*N/A* not applicable^a^It is assumed minor stroke and systemic embolism have a case-fatality of 0 % and thus mortality rate is equal to that in the general population^b^Assumed identical to post-major stroke mortality rate

Drug and Event Costs {#Sec5}
--------------------

Three relevant cost categories were identified: drug acquisition costs, drug administration/monitoring costs, and events costs (Table [3](#Tab3){ref-type="table"}; Online Resource 1). Based on the market shares and pack sizes of the brands that are locally available, a weighted average drug cost of €0.31 and €0.07 was estimated for VKAs and aspirin, respectively. For rivaroxaban, an average cost of €2.70 per tablet was assumed. When patients are initiated on warfarin therapy, it is recommended that they visit their physician regularly to make the dose adjustments required to maintain the target INR of 2.5 (typical target range is 2.0--3.0). Based on a report of the Belgian health care knowledge centre (KCE), it was assumed that these patients have 15 general practitioner (GP) visits (€29 per visit) and INR laboratory tests (€15.8 per test) per year, or 3.75 per Markov cycle \[[@CR21]\]. For aspirin and rivaroxaban, the model assumes that patients would visit their GP two times per year (range 0--8 GP visits) as no monitoring is required for these therapies. At the time the present pharmacoeconomic evaluation was prepared for submission to local reimbursement authorities, costs were inflated to the year 2010 using the appropriate annual Health Index figures as recommended by the Belgian KCE guidelines \[[@CR22]\].Table 3Overview of drug, monitoring, and event costs \[[@CR33], [@CR34]; Online Resource 1\]ItemDrug costs (per tablet) \[€\]Consultation^e^ and INR monitoring costs (per visit) \[€\]Rivaroxaban^a^2.7029.08Vitamin K antagonist^b^0.3144.85Aspirin^b^0.0729.08Event^c^Acute (per event) \[€\]Rehabilitation^f^ (per event) \[€\]Long-term follow-up (per 3 months) \[€\]Minor stroke5,9463,204244Major stroke12,24717,7342,216Systemic embolism5,124----CRNM extracanial bleed23----Major extracanial bleed3,510----Intracranial bleed^d^7,69917,7342,216Myocardial infarction7,891----*CRNM* clinically relevant non-major, *INR* international normalized ratio^a^Assuming 5 and 95 % of tablets from the 28- (€98.82) and 98-tablet (€260.23) drug packages sizes, respectively^b^Based on market share and prices of locally available brands^c^The range of event costs tested in sensitivity analyses was ±25 % of the mean^d^Costs of rehabilitation and long-term follow-up were assumed identical, as for major stroke^e^Includes home consultations^f^Based on unpublished results, (Putman K, personal communication)

Health-Related Outcomes {#Sec6}
-----------------------

A systematic search was performed to identify health state utility values in AF, stroke, post-stroke, embolism, myocardial infarction, and bleeding events occurring in a non-valvular AF population. The baseline utility for an untreated AF patient aged 73 years was set at 0.799 (Table [4](#Tab4){ref-type="table"}). Utility scores specific to Belgium were not identified during the search. Although it is generally accepted that the need for constant monitoring can adversely affect the quality of life \[[@CR23]--[@CR25]\], a disutility for warfarin treatment was not applied in the base-case analysis. Table [4](#Tab4){ref-type="table"} shows the health state utility values and ranges used in the analysis.Table 4Overview of utility values (range)DescriptionCurrently value in the modelDistribution (SD)ReferencePopulationCountryMeanRangeStable---not on therapy0.7990.635--1Beta (*a* = 14.0, *b* = 3.5)Dagres et al. \[[@CR35]\]Patients with atrial fibrillation enrolled in the Euro Heart Survey on Atrial Fibrillation, mean age 67 yearsEuropeStable---on warfarin therapy0.7990.635--1N/ADagres et al. \[[@CR35]\]Patients with atrial fibrillation enrolled in the Euro Heart Survey on Atrial Fibrillation, mean age 67 yearsEuropeUtility decrement used for warfarin1.0000.920--1N/ARobinson et al. \[[@CR36]\]Patients with atrial fibrillation, male and female, mean age 73 yearsUKStable---on other therapy0.7990.635--1N/AAssumed = not on therapyN/AN/AStable---initiating warfarin therapy0.7990.635--1N/AAssumed = stable on warfarinN/AN/AUtility decrement used for initiating warfarin1.0000.920--1N/ARobinson et al. \[[@CR36]\]Patients with atrial fibrillation, male and female, mean age 73 yearsUKEmbolic events Minor stroke0.6410.550--0.660Beta (*a* = 187, *b* = 105)Robinson et al. \[[@CR36]\]Patients with atrial fibrillation, male and female, mean age 73 yearsUK Post-minor stroke0.7270.538--0.772Beta (*a* = 40, *b* = 15)Hallan et al. \[[@CR37]\]Stroke survivors, mean age 65 yearsNorway Major stroke0.1890.142--0.236Beta (*a* = 50, *b* = 213)Robinson et al. \[[@CR36]\]Patients with atrial fibrillation, male and female, mean age 73 yearsUK Post-major stroke0.4870.078--0.710Beta (*a* = 4.2, *b* = 4.4)Hallan et al. \[[@CR37]\]Stroke survivors, mean age 65 yearsNorway Systemic embolism0.6790.660--0.692Beta (*a* = 2251, *b* = 1061)Sullivan et al. \[[@CR38]\]Patients with systemic embolic event (ICD-9 444)USBleeding events Minor bleed0.7960.794--0.789Beta (*a* = 34, *b* = 9)Sullivan et al. \[[@CR38]\]Patients with systemic embolic event (ICD-9 444)US Major bleed0.6180.590--0.645Beta (*a* = 762, *b* = 470)Sullivan et al. \[[@CR38]\]Patients with systemic embolic event (ICD-9 444)US Intracranial bleed0.6000.020--0.635Beta (*a* = 1.7 *b* = 1.1)Lenert and Soetikno \[[@CR39]\]Deep venous thrombosis, 20--40 for female volunteersUS Post-intracranial bleed0.7400.078--0.772Beta (*a* = 3.8, *b* = 1.3)Haacke et al. \[[@CR40]\]Patients with an ischemic, transient ischemic or hemorrhagic stroke, mean age 74.6 yearsGermanyMyocardial infarction events Myocardial infarction0.6670.501--0.799Beta (*a* = 25, *b* = 12)Robinson et al. \[[@CR42]\]Patients with acute myocardial infarctionUK Post-myocardial infarction0.7030.528--0.799Beta (*a* = 30, *b* = 13)Sanders et al. \[[@CR41]\]Patients with past myocardial infarction who did not have sustained ventricular arrhythmiaUS Death0.0000N/ADefinitionN/AN/A*ICD* International Classification of Diseases, *N/A* not applicable

Analysis {#Sec7}
--------

The model's primary outcomes were the number of life-years, quality-adjusted life-years (QALYs), and life-threatening events per patient. In the base-case cost-effectiveness analysis, an ICER was calculated as the difference in costs divided by the difference in outcomes associated with the two treatments. In accordance with local guidelines, future costs were discounted at a rate of 3 %, and future outcomes were discounted at a rate of 1.5 % \[[@CR22]\]. In order to fully incorporate the costs and outcomes of AF, the time horizon was set to describe the lifetime of treated patients. A one-way sensitivity analysis and a probabilistic sensitivity analysis (PSA) were performed to evaluate the impact a change in input variables may have on the model's results. In these analyses, a beta distribution was used for model transition probabilities (event rates) and utility parameters, while relative risk parameters and costs were assumed to have a log-normal distribution, and a gamma distribution was used for resource use \[[@CR18]\]. Base-case estimates were adjusted based on 95 % CIs from the analysis of the ROCKET AF trial. Alternatively, point estimates for costs varied by 25 %, which was considered sufficient variation to capture relevant uncertainty. Both the development and the adaptation of this model to the Belgian environment were validated by a number of leading clinicians and health economists. During the validation process, the model's structure, logic, input data, key assumptions, mathematical steps and functionalities were thoroughly tested.

Results {#Sec8}
=======

Base-Case Analysis {#Sec9}
------------------

In the base-case analysis, rivaroxaban treatment was associated with fewer ischemic strokes and systemic embolisms (0.308 vs. 0.321 events per patient), intracranial bleeds (0.048 vs. 0.063), and myocardial infarctions (0.082 vs. 0.095) compared with warfarin treatment. Consequently, patients treated with rivaroxaban gained more QALYs (8.213 vs. 8.119) and life-years (10.621 vs. 10.510). Over a lifetime time horizon, rivaroxaban treatment led to a reduction of 0.042 life-threatening events per patient, an increase of 0.094 QALYs and 0.111 life-years compared with warfarin treatment. This resulted in an ICER of €8,809 per QALY or €7,493 per life-year gained (Table [5](#Tab5){ref-type="table"}). In a secondary analysis, using clinical data of ROCKET AF's intention-to-treat population, the ICER was determined at €14,970 per QALY and €11,897 per life-year gained.Table 5Cost-effectiveness results and events avoided over the lifetime of patientsEvents per 1,000 patientsRivaroxabanWarfarinDifferenceIschemic strokes and systemic embolisms308321−13Intracranial bleedings4863−16Myocardial infarctions8295−13Cost and effectiveness results per patient Life-years10.62110.5100.111 QALY8.2138.1190.094 Costs (€)18,69517,867828 Incremental cost-effectiveness ratio (€)8,809 per QALY gained*QALY* quality-adjusted life-years

Sensitivity Analysis {#Sec10}
--------------------

Results from the one-way sensitivity analysis indicated that the relative risk of rivaroxaban vs. warfarin for stroke, the number of GP/monitoring visits, baseline intracranial bleed rate, and the treatment discontinuation rates were the main drivers of the cost-effectiveness analysis (Fig. [2](#Fig2){ref-type="fig"}). While, for example, the ICER was estimated at €5,193 per QALY gained should a patient on rivaroxaban no longer need to visit a physician, it would be around €19,659 per QALY if eight GP visits are required annually. Results from the PSA, based on 10,000 iterations, are presented in Fig. [3](#Fig3){ref-type="fig"} and suggest that rivaroxaban is cost-effective compared with warfarin therapy in 66, 79, and 87 % of cases if a willingness-to-pay threshold of €10,000, €20,000 or €35,000 per additional QALY were to be considered, respectively.Fig. 2Tornado diagram showing the main drivers (variables and sensitivity ranges) of the incremental cost-effectiveness ratio (ICER)Fig. 3Cost-effectiveness acceptability curve

Discussion {#Sec11}
==========

The above-mentioned results suggest that, in the Belgian healthcare setting, rivaroxaban is a cost-effective alternative to warfarin for the prevention of stroke in AF patients. The incremental cost of rivaroxaban over warfarin was calculated to be €828 over the patient's lifetime in the base-case analysis. As warfarin is an off-patent drug, its drug acquisition costs are lower than these of novel innovative drugs such as rivaroxaban. This difference, however, was largely compensated by the decrease in costs related to monitoring and treatment of events. At the same time, the incremental health gain was estimated at a value close to 0.09 QALYs. These figures generate an ICER of approximately €8,809/QALY gained. Per 1,000 patients treated with rivaroxaban, an estimated 42 life-threatening events would be avoided.

One-way sensitivity analysis showed that only two variables were able to drive the ICER beyond a value of €25,000 per QALY. First, the ICER was most sensitive to the relative risk of ischemic stroke for rivaroxaban, indicating that the new treatment may not be cost-effective if it were to be associated with more strokes than warfarin. Results from the ROCKET AF trial, however, suggest that rivaroxaban (149 cases in 7,061 patients) is not less effective than warfarin (161 cases in 7,082 patients) in preventing ischemic strokes. Secondly, a higher cost of warfarin monitoring driven by more frequent visits during the maintenance phase yields a lower ICER. As its predictable anticoagulant effect makes routine monitoring redundant, patients on rivaroxaban will need to visit their GP much less frequently. Based on a report issued by the Belgian KCE \[[@CR21]\], we have accepted there would be 15 dose monitoring/adjustment visits per year for warfarin and assumed there would be 2 for rivaroxaban. It was considered likely that the additional, regular clinical attention patients receive from their physician, independent of dose monitoring, would be comparable in both groups.

In addition, the PSA showed that the likelihood of rivaroxaban being cost-effective or even cost saving is very high. Taken together, the results of the deterministic and PSAs thus strongly support the conclusion that rivaroxaban is a cost-effective alternative to warfarin. This is in line with earlier findings from a model developed by Lee and colleagues, which already suggested that rivaroxaban therapy was cost-effective versus adjusted-dose warfarin for stroke prevention in AF in the US healthcare setting \[[@CR26]\].

As any economic model, the present analysis has some limitations. One of the limitations was the use of a cohort Markov model for the cost-effectiveness analysis, which is limited in tracking the patient's history. For example, the risk of a second stroke is elevated over the first stroke, however this was not incorporated in the model. Another limitation of the model is that no Belgian-specific utilities could be found. However, the international values that were identified and used in the model are likely to be representative for the Belgian population because all the utility values were obtained from either a European country or the US, and from a patient population that corresponds to the Belgian population treated for stroke prevention in atrial fibrillation (SPAF) (Table [4](#Tab4){ref-type="table"}). Moreover, it should be noted that the ICERs were not very sensitive to changes in utility values, so this limitation would only have a minimal impact on the overall results.

A Belgian health economic study for dabigatran versus warfarin resulted also in dabigatran being considered cost-effective \[[@CR27]\], but a direct comparison between rivaroxaban and dabigatran is not possible because there are no head-to-head trials. An indirect comparison is possible \[[@CR28]\] but not robust because of the significant differences in the study population and study design of ROCKET AF, RE-LY and ARISTOTLE. A systematic review between the three NOACs (rivaroxaban, dabigatran, apixaban) concluded that NOACs are cost-effective but the lack of head-to-head trials and the heterogeneous characteristics of underlying trials and modelling methods make it difficult to determine the most cost-effective agent \[[@CR29]\].

Its predictable anticoagulant effects and low propensity for drug interactions gives rivaroxaban not only an economical advantage but also a major clinical advantage over VKA therapy. Because of the challenges that are associated with warfarin therapy, many Belgian patients with moderate to high risk (CHADS~2~ score ≥2) are currently being treated with aspirin (24 %) or receive no prophylaxis at all (25 %). Moreover, not all patients receiving warfarin therapy may actually get optimal anticoagulation. In fact, a cross-sectional study involving 66 general practices in Belgium showed that only 69 % of the day values obtained over a period of 6 months fell within a target range of 0.75 INR units (1.75--3.25) \[[@CR30]\]. In the ROCKET AF trial, however, the target range was lower (0.5 INR units; 2.0--3.0) and, consistent with this, a lower proportion of the day values (55 %) fell within the INR target range. The lower proportion of day values in the trial is likely due to the lower INR target range and can also be due to the difference in performance level of warfarin in the trial compared with real life. Since the data from the trial were used in the model, the proportion of patients who receive optimal anticoagulation therapy with warfarin might have been slightly underestimated. If that is true, this affected the ICER in favour of rivaroxaban, although this is difficult to ascertain given the difference in INR target range. Both VKA-treated and untreated patients may thus remain at high risk for stroke. In addition, the simple dosing regimen of rivaroxaban (oral, once daily) may help patients adhere to therapy, which in real life could lead to more patients reaching optimum coagulation with rivaroxaban, thereby reducing the burden of AF-related stroke.

Conclusion {#Sec12}
==========

The present analysis suggests that rivaroxaban is a cost-effective alternative to warfarin therapy for the prevention of stroke in patients with AF in the Belgian healthcare setting.
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